Ultragenyx Pharmaceutical Stock Price, News & Analysis (NASDAQ:RARE)

$45.24 -0.33 (-0.72 %)
(As of 12/12/2017 01:10 AM ET)
Previous Close$45.57
Today's Range$45.22 - $46.69
52-Week Range$44.02 - $91.35
Volume405,800 shs
Average Volume439,084 shs
Market Capitalization$1.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.83

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:RARE
CUSIPN/A
Phone+1-415-4838800

Debt

Debt-to-Equity RatioN/A
Current Ratio6.08%
Quick Ratio6.08%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$130,000.00
Price / Sales14,821.32
Cash FlowN/A
Price / CashN/A
Book Value$11.60 per share
Price / Book3.90

Profitability

Trailing EPS($6.97)
Net Income$-245,870,000.00
Net MarginsN/A
Return on Equity-66.39%
Return on Assets-57.79%

Miscellaneous

Employees376
Outstanding Shares42,590,000

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($1.87). The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.02 million. The business's quarterly revenue was up 81.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.64) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

When will Ultragenyx Pharmaceutical make its next earnings announcement?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 15th 2018. View Earnings Estimates for Ultragenyx Pharmaceutical.

Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?

17 analysts have issued 1 year target prices for Ultragenyx Pharmaceutical's shares. Their predictions range from $55.00 to $85.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $72.40 in the next year. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (11/8/2017)
  • 2. J P Morgan Chase & Co analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
  • 3. Cowen Inc analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)
  • 4. Canaccord Genuity analysts commented, "INSM’s Ph3 Arikayce NTM CONVERT trial data is due ~September of this year." (5/8/2017)
  • 5. Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)

Who are some of Ultragenyx Pharmaceutical's key competitors?

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board (Age 59)
  • Emil D. Kakkis M.D. Ph.D., President, Chief Executive Officer, Director (Age 57)
  • Shalini Sharp, Chief Financial Officer, Executive Vice President (Age 42)
  • Sunil Agarwal M.D., President - Research and Development (Age 47)
  • Karah Parschauer, Executive Vice President, General Counsel (Age 39)
  • Jayson Dallas M.D., Chief Commercial Officer and Executive Vice President (Age 49)
  • Dennis Karl Huang, Chief Technical Operations Officer, Executive Vice President (Age 52)
  • Thomas Kassberg, Chief Business Officer, Executive Vice President (Age 56)
  • John R. Pinion II, Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research (Age 51)
  • William E. Aliski, Independent Director (Age 69)

Who owns Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Capital International Investors (6.80%), Pictet Asset Management Ltd. (1.77%), First Trust Advisors LP (1.24%), Capital Guardian Trust Co. (1.22%), Eagle Asset Management Inc. (1.12%) and Rockefeller Financial Services Inc. (0.94%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Who sold Ultragenyx Pharmaceutical stock? Who is selling Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Jennison Associates LLC, Ameriprise Financial Inc., Schwab Charles Investment Management Inc., Iguana Healthcare Management LLC, Point72 Asset Management L.P., Rockefeller Financial Services Inc. and California State Teachers Retirement System. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Who bought Ultragenyx Pharmaceutical stock? Who is buying Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Pictet Asset Management Ltd., Abingworth LLP, AXA, Brown Advisory Inc., First Trust Advisors LP, State of Wisconsin Investment Board and Cowen Inc.. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy Ultragenyx Pharmaceutical stock?

Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $45.24.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $1.94 billion and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-245,870,000.00 in net income (profit) each year or ($6.97) on an earnings per share basis. Ultragenyx Pharmaceutical employs 376 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Ct, NOVATO, CA 94949-5746, United States. The biopharmaceutical company can be reached via phone at +1-415-4838800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (RARE)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  466 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ultragenyx Pharmaceutical (NASDAQ:RARE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldBuy
Consensus Rating Score: 2.552.472.422.56
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $73.50$73.00$74.17$84.00
Price Target Upside: 47.12% upside47.39% upside47.54% upside39.58% upside

Ultragenyx Pharmaceutical (NASDAQ:RARE) Consensus Price Target History

Price Target History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017Raymond James FinancialReiterated RatingBuyMediumView Rating Details
12/5/2017Canaccord GenuitySet Price TargetBuy$80.00MediumView Rating Details
12/5/2017BarclaysBoost Price TargetEqual Weight -> Equal Weight$60.00 -> $62.00HighView Rating Details
12/4/2017Jefferies GroupUpgradeHold -> Buy$58.00 -> $72.00HighView Rating Details
11/15/2017CowenReiterated RatingBuyN/AView Rating Details
11/5/2017J P Morgan Chase & CoReiterated RatingBuy$76.00N/AView Rating Details
11/3/2017Robert W. BairdLower Price TargetOutperform$85.00 -> $80.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$69.00 -> $71.00N/AView Rating Details
9/14/2017WedbushUpgradeNeutral -> Outperform$62.00HighView Rating Details
8/23/2017JMP SecuritiesLower Price TargetMarket Outperform$90.00 -> $80.00LowView Rating Details
8/23/2017Stifel NicolausReiterated RatingBuy$95.00 -> $85.00HighView Rating Details
8/23/2017Leerink SwannReiterated RatingOutperform$89.00 -> $83.00HighView Rating Details
8/23/2017SunTrust BanksDowngradeBuy -> Hold$105.00 -> $55.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$63.00HighView Rating Details
8/8/2017HC WainwrightReiterated RatingNeutral -> Neutral$72.00 -> $75.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00HighView Rating Details
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> NeutralHighView Rating Details
11/30/2016CitigroupDowngradeNeutral -> SellN/AView Rating Details
9/14/2016Credit Suisse GroupReiterated RatingBuy$101.00N/AView Rating Details
6/28/2016Bank of AmericaInitiated CoverageBuy$72.00N/AView Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earnings History and Estimates Chart

Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ RARE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($1.96)N/AView Earnings Details
11/2/2017Q3 2017($1.87)($1.87)$0.02 million$0.20 millionViewN/AView Earnings Details
7/27/2017Q2 2017($1.73)($1.72)$0.01 millionViewN/AView Earnings Details
5/4/2017Q1 2017($1.71)($1.63)$0.05 millionViewListenView Earnings Details
2/16/2017Q4 2016($1.72)($1.75)$0.05 million$0.01 millionViewN/AView Earnings Details
11/7/2016Q3($1.53)($1.64)$7.60 million$0.11 millionViewListenView Earnings Details
8/8/2016Q2($1.44)($1.46)$0.02 millionViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earnings Estimates

2017 EPS Consensus Estimate: ($7.36)
2018 EPS Consensus Estimate: ($7.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.82)($1.69)($1.75)
Q2 20174($1.93)($1.59)($1.76)
Q3 20174($2.01)($1.62)($1.85)
Q4 20174($2.21)($1.67)($2.00)
Q1 20183($2.13)($1.87)($2.01)
Q2 20183($2.13)($1.89)($2.04)
Q3 20183($1.94)($0.78)($1.54)
Q4 20183($2.12)($1.77)($1.96)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ultragenyx Pharmaceutical (NASDAQ RARE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 94.13%
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ RARE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/28/2017Emil D KakkisCEOBuy7,500$52.52$393,900.00View SEC Filing  
5/26/2017Theodore Alan HuizengaVPSell480$57.46$27,580.80View SEC Filing  
3/9/2017Theodore Alan HuizengaInsiderSell2,500$86.34$215,850.00View SEC Filing  
3/2/2017Shalini SharpCFOSell12,000$90.10$1,081,200.00View SEC Filing  
2/27/2017Shalini SharpCFOSell12,000$80.14$961,680.00View SEC Filing  
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.00View SEC Filing  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.00View SEC Filing  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.00View SEC Filing  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00View SEC Filing  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ultragenyx Pharmaceutical (NASDAQ RARE) News Headlines

Source:
DateHeadline
Ultragenyx Pharmaceutical (RARE) Given a $80.00 Price Target at Canaccord GenuityUltragenyx Pharmaceutical (RARE) Given a $80.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - December 10 at 12:46 AM
Ultragenyx Looks To Treat Rare Bone Disease - Seeking AlphaUltragenyx Looks To Treat Rare Bone Disease - Seeking Alpha
seekingalpha.com - December 9 at 11:22 AM
Ultragenyx Pharmaceutical Inc. to Post Q2 2018 Earnings of ($2.11) Per Share, Wedbush Forecasts (RARE)Ultragenyx Pharmaceutical Inc. to Post Q2 2018 Earnings of ($2.11) Per Share, Wedbush Forecasts (RARE)
www.americanbankingnews.com - December 8 at 9:28 AM
Ultragenyx Pharmaceutical Inc. (RARE) Receives Consensus Recommendation of "Buy" from BrokeragesUltragenyx Pharmaceutical Inc. (RARE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 8 at 8:06 AM
Ultragenyx Pharmaceutical Inc. Expected to Post FY2017 Earnings of ($7.45) Per Share (RARE)Ultragenyx Pharmaceutical Inc. Expected to Post FY2017 Earnings of ($7.45) Per Share (RARE)
www.americanbankingnews.com - December 8 at 6:18 AM
Ultragenyx Pharmaceuticals (RARE) "Buy" Rating Reiterated at Raymond James FinancialUltragenyx Pharmaceutical's (RARE) "Buy" Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - December 6 at 5:00 PM
FY2018 EPS Estimates for Ultragenyx Pharmaceutical Inc. (RARE) Reduced by Jefferies GroupFY2018 EPS Estimates for Ultragenyx Pharmaceutical Inc. (RARE) Reduced by Jefferies Group
www.americanbankingnews.com - December 6 at 2:46 PM
Ultragenyx Pharmaceutical (RARE) Price Target Raised to $62.00 at BarclaysUltragenyx Pharmaceutical (RARE) Price Target Raised to $62.00 at Barclays
www.americanbankingnews.com - December 5 at 1:30 PM
Ultragenyx Pharmaceutical (RARE) Upgraded at Jefferies GroupUltragenyx Pharmaceutical (RARE) Upgraded at Jefferies Group
www.americanbankingnews.com - December 4 at 7:32 PM
Ultragenyx Pharma (RARE), Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab in X-Linked HypophosphatemiaUltragenyx Pharma (RARE), Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab in X-Linked Hypophosphatemia
www.streetinsider.com - December 4 at 3:36 PM
Does This Rare-Disease Biotech Have A Winner On Its Hands?Does This Rare-Disease Biotech Have A Winner On Its Hands?
finance.yahoo.com - December 4 at 3:36 PM
Ultragenyx Pharma (RARE), Kyowa Kirin Announce Positive 48 ... - StreetInsider.comUltragenyx Pharma (RARE), Kyowa Kirin Announce Positive 48 ... - StreetInsider.com
www.streetinsider.com - December 4 at 11:58 AM
Ultragenyx shares rise 4% on late-stage results for rare disease therapyUltragenyx shares rise 4% on late-stage results for rare disease therapy
finance.yahoo.com - December 4 at 11:58 AM
Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech MoversIronwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers
finance.yahoo.com - December 4 at 11:58 AM
Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : December 1, 2017Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : December 1, 2017
finance.yahoo.com - December 1 at 5:01 PM
Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4
finance.yahoo.com - November 30 at 12:04 PM
 Brokerages Expect Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $420,000.00 Brokerages Expect Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $420,000.00
www.americanbankingnews.com - November 28 at 6:56 AM
Zacks: Brokerages Expect Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Earnings of -$1.96 Per ShareZacks: Brokerages Expect Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Earnings of -$1.96 Per Share
www.americanbankingnews.com - November 26 at 3:14 PM
ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 20, 2017ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 20, 2017
finance.yahoo.com - November 21 at 9:43 AM
Ultragenyx Pharmaceutical Inc. to Post Q4 2017 Earnings of ($2.03) Per Share, SunTrust Banks Forecasts (RARE)Ultragenyx Pharmaceutical Inc. to Post Q4 2017 Earnings of ($2.03) Per Share, SunTrust Banks Forecasts (RARE)
www.americanbankingnews.com - November 20 at 4:32 AM
Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) DeficiencyUltragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
finance.yahoo.com - November 18 at 11:13 AM
Ultragenyx Pharmaceutical Inc. (RARE) Given New $80.00 Price Target at Canaccord GenuityUltragenyx Pharmaceutical Inc. (RARE) Given New $80.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - November 16 at 4:51 PM
Ultragenyx Pharmaceuticals (RARE) Buy Rating Reaffirmed at Cowen and CompanyUltragenyx Pharmaceutical's (RARE) Buy Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - November 15 at 11:36 PM
Ultragenyx Pharmaceutical Inc. (RARE) Receives Consensus Rating of "Hold" from BrokeragesUltragenyx Pharmaceutical Inc. (RARE) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 8:14 AM
 Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $100,000.00 Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $100,000.00
www.americanbankingnews.com - November 10 at 11:13 AM
ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 8, 2017ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 12:16 PM
Ultragenyx Pharmaceutical Inc. (RARE) Rating Increased to Hold at Zacks Investment ResearchUltragenyx Pharmaceutical Inc. (RARE) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - November 8 at 9:43 AM
Ultragenyx to Present at the Credit Suisse Healthcare ConferenceUltragenyx to Present at the Credit Suisse Healthcare Conference
finance.yahoo.com - November 7 at 9:20 AM
Ultragenyx Pharmaceutical, Inc. :RARE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Ultragenyx Pharmaceutical, Inc. :RARE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 9:20 AM
Ultragenyx Completes Tender Offer and Acquisition of Dimension TherapeuticsUltragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
finance.yahoo.com - November 7 at 9:19 AM
Ultragenyx Pharmaceutical Inc. Forecasted to Earn Q1 2018 Earnings of ($1.75) Per Share (RARE)Ultragenyx Pharmaceutical Inc. Forecasted to Earn Q1 2018 Earnings of ($1.75) Per Share (RARE)
www.americanbankingnews.com - November 6 at 9:56 AM
Ultragenyx reports 3Q lossUltragenyx reports 3Q loss
finance.yahoo.com - November 6 at 6:23 AM
Ultragenyx Pharmaceutical Inc. (RARE) Receives Buy Rating from J P Morgan Chase & CoUltragenyx Pharmaceutical Inc. (RARE) Receives Buy Rating from J P Morgan Chase & Co
www.americanbankingnews.com - November 5 at 8:56 AM
Ultragenyx Pharmaceutical Inc. (RARE) PT Lowered to $80.00 at Robert W. BairdUltragenyx Pharmaceutical Inc. (RARE) PT Lowered to $80.00 at Robert W. Baird
www.americanbankingnews.com - November 5 at 7:16 AM
Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate UpdateUltragenyx Reports Third Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - November 4 at 10:09 AM
Edited Transcript of RARE earnings conference call or presentation 2-Nov-17 9:00pm GMTEdited Transcript of RARE earnings conference call or presentation 2-Nov-17 9:00pm GMT
finance.yahoo.com - November 4 at 10:09 AM
Ultragenyx Pharmaceutical Inc. (RARE) Issues  Earnings ResultsUltragenyx Pharmaceutical Inc. (RARE) Issues Earnings Results
www.americanbankingnews.com - November 2 at 10:40 PM
Ultragenyx Pharma (RARE) and Kyowa Hakko Kirin Say FDA isnt Planning to Hold Advisory Committee Meeting for Burosumab BLAUltragenyx Pharma (RARE) and Kyowa Hakko Kirin Say FDA isn't Planning to Hold Advisory Committee Meeting for Burosumab BLA
www.streetinsider.com - November 2 at 8:11 AM
Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold Advisory Committee Meeting for Burosumab Biologics License ApplicationUltragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold Advisory Committee Meeting for Burosumab Biologics License Application
finance.yahoo.com - November 2 at 8:11 AM
Ultragenyx Pharmaceuticals: RARE Opportunity To ProfitUltragenyx Pharmaceuticals: RARE Opportunity To Profit
seekingalpha.com - October 31 at 8:29 AM
Ultragenyx to Host Conference Call for Third Quarter 2017 Financial Results and Corporate UpdateUltragenyx to Host Conference Call for Third Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - October 31 at 8:29 AM
Comparing Ultragenyx Pharmaceutical (RARE) and Its CompetitorsComparing Ultragenyx Pharmaceutical (RARE) and Its Competitors
www.americanbankingnews.com - October 30 at 9:22 PM
Ultragenyx Pharmaceutical Inc. (RARE) Set to Announce Earnings on MondayUltragenyx Pharmaceutical Inc. (RARE) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 30 at 3:28 AM
Ultragenyx Pharmaceutical (RARE) and The Competition Head-To-Head ReviewUltragenyx Pharmaceutical (RARE) and The Competition Head-To-Head Review
www.americanbankingnews.com - October 28 at 9:28 AM
Ultragenyx Pharma (RARE), Dimension (DMTX) Announce Expiration of HSR Waiting Period for Ultragenyxs ... - StreetInsider.comUltragenyx Pharma (RARE), Dimension (DMTX) Announce Expiration of HSR Waiting Period for Ultragenyx's ... - StreetInsider.com
www.streetinsider.com - October 27 at 12:56 PM
Ultragenyx Pharmaceutical is Now Oversold (RARE) - Nasdaq.com - NasdaqUltragenyx Pharmaceutical is Now Oversold (RARE) - Nasdaq.com - Nasdaq
www.nasdaq.com - October 27 at 12:56 PM
Is There Now An Opportunity In Ultragenyx Pharmaceutical Inc (RARE)?Is There Now An Opportunity In Ultragenyx Pharmaceutical Inc (RARE)?
finance.yahoo.com - October 22 at 6:08 AM
Zacks: Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $70,000.00Zacks: Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $70,000.00
www.americanbankingnews.com - October 21 at 9:46 AM
-$1.87 EPS Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter-$1.87 EPS Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter
www.americanbankingnews.com - October 19 at 6:24 AM
CRY Opens Wallet, LLYs JUNIPER Flops, MDXG Catches Eyes ... - NasdaqCRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes ... - Nasdaq
www.nasdaq.com - October 11 at 6:56 AM

SEC Filings

Ultragenyx Pharmaceutical (NASDAQ:RARE) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Ultragenyx Pharmaceutical (NASDAQ:RARE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ultragenyx Pharmaceutical (NASDAQ RARE) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.